The DNA ligase IV inhibitor, SCR-7, was also tested in K562 and primary CD34+ HSPCs edited with AAV6 and Cas9; unlike previous reports in human cancer cell lines and porcine fibroblasts, SCR-7 did not improve HDR editing in K562 cells or CD34+ HSPCs [27,90]. This evidence concerns the gene CD34 and cancer.